Promising Results for Lurbinectedin in SCLC When Paired with Irinotecan

Deeper Understanding of EGFR Mutation Subgroups Will Further Personalize Treatment for NSCLC

Trastuzumab Deruxtecan Potential New Treatment Options for HER2+ NSCLC

New Nodal Descriptor Classification Potentially Better at Differentiating Patients

Targeting KRAS in Lung Cancer: The Past, Present, and Future 

Envisioning A Tobacco-Free Generation

Nivolumab Boosted Survival in Relapsed Mesothelioma

Sotorasib Shows Early Activity Against KRAS G12C Mutant NSCLC

KEYNOTE-598: Dual PD-1 and CTLA-4 Checkpoint Blockade Confers No Therapeutic Benefit Beyond PD-1 Blockade Alone in PD-L1–Positive NSCLC

LCMC3 Findings Indicate Neoadjuvant Atezolizumab Safe, Efficacious in Resectable Stage IB-IIIB NSCLC

Genetically Tailored Treatment Approach Did Not Improve Survival in Stage II-III NSCLC